PubRank

Catherine Lhommé

Author PubWeight™ 39.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol 2004 1.75
2 Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2010 1.53
3 Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003 1.40
4 Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol 2009 1.18
5 Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003 1.13
6 Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique). Hum Reprod 2005 1.11
7 Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity. Ann Surg Oncol 2007 1.08
8 Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer. Oncologist 2010 1.05
9 Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol 2006 1.02
10 Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002 0.94
11 A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013 0.92
12 Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011 0.90
13 Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer 2010 0.90
14 Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary. Oncologist 2011 0.90
15 Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy. Radiother Oncol 2008 0.88
16 Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 2010 0.87
17 Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression. Eur J Obstet Gynecol Reprod Biol 2006 0.87
18 Outcome after salvage radiotherapy (brachytherapy +/- external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol 2002 0.86
19 Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol 2004 0.84
20 Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist 2009 0.83
21 Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 2006 0.82
22 [The molecular biology of epithelial ovarian cancer]. Bull Cancer 2012 0.82
23 Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging. Clin Imaging 2012 0.82
24 Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma. Gynecol Oncol 2005 0.81
25 Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003 0.80
26 Gynecologic bleeding revealing vaginal metastasis of renal cell carcinoma. Pan Afr Med J 2013 0.80
27 [Standards, Options and Recommendations for the management of invasive cervical cancer patients (non metastastic)]. Bull Cancer 2003 0.80
28 Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod 2011 0.80
29 Impact of epidural analgesia on survival in patients undergoing complete cytoreductive surgery for ovarian cancer. Anticancer Res 2012 0.79
30 [Gynecological cancers and pregnancy: the point of view of the oncology gynecologist]. Bull Cancer 2002 0.78
31 [Conservative management of malignant and borderline ovarian tumor]. Bull Cancer 2002 0.78
32 Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol 2007 0.78
33 [Ovarian yolk sac tumour: general review]. Bull Cancer 2011 0.77
34 [Medical treatment of metastatic or recurrent cancer of the cervix]. Bull Cancer 2006 0.77
35 Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Invest New Drugs 2006 0.77
36 [Systemic therapy for advanced endometrial cancer]. Bull Cancer 2012 0.76
37 Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril 2006 0.76
38 Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol 2007 0.76
39 Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Int J Gynecol Cancer 2015 0.76
40 Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynaecol Obstet 2013 0.76
41 Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. Eur J Obstet Gynecol Reprod Biol 2009 0.76
42 Cancer during pregnancy: the time has come for a prospective program. J Clin Oncol 2009 0.76
43 [Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment]. Bull Cancer 2013 0.76
44 [Concomitant chemoradiation in patients with cervix cancer]. Bull Cancer 2005 0.76
45 Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005 0.75
46 A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. Chemotherapy 2015 0.75
47 [French recommendations for endometrial cancer 2010: clinical use and questions still debated]. Bull Cancer 2012 0.75
48 [Postoperative vaginal brachytherapy in endometrial cancer]. Bull Cancer 2012 0.75
49 Correlation between macroscopic and microscopic diseases on splenectomies performed in the surgical management of ovarian cancer. Int J Gynecol Cancer 2010 0.75
50 [Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer]. Bull Cancer 2007 0.75
51 Sentinel lymph node in endometrial cancer: a review. Curr Oncol Rep 2013 0.75
52 Endometrial disorders in patients with peritoneal serous papillary carcinoma. Eur J Obstet Gynecol Reprod Biol 2006 0.75